{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:11:44Z","timestamp":1777957904302,"version":"3.51.4"},"reference-count":49,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Molnupiravir is an orally administered prodrug of \u03b2\u2010D\u2010N4\u2010hydroxycytidine (NHC) that is conditionally approved in China for the treatment of mild to moderate COVID\u201019 in nonhospitalized adults at high risk of disease progression. Molnupiravir is rapidly absorbed and hydrolyzed to deliver NHC into systemic circulation. An open\u2010label, fixed\u2010sequence, Phase 1 study was conducted to evaluate the tolerability, safety, and pharmacokinetics (PK) following single and multiple (every 12\u2009h for 5.5\u2009days) oral dosing of molnupiravir 800\u2009mg in 16 healthy, male Chinese participants. After multiple doses of molnupiravir, the median time to maximum concentration was 2.0\u2009h for plasma NHC. NHC concentrations generally decreased in a biphasic manner, with a terminal half\u2010life of 21.9\u2009h, and NHC exposures (i.e., area under the curve and maximum plasma concentration) were similar following single and multiple doses of molnupiravir. No accumulation of NHC in plasma was observed. When compared with historical data from published clinical trials of similar study design, NHC exposure in Chinese participants was marginally higher than that in non\u2010Asian participants but remained within established clinical bounds. Overall, molnupiravir was generally well\u2010tolerated. Ten participants (63.5%) experienced at least one adverse event throughout the study, the severity of which was mild or moderate, and none led to treatment discontinuation. There were no clinically meaningful findings in other safety evaluations. These data support use of the standard 5\u2010day regimen of molnupiravir 800\u2009mg every 12\u2009h without dose adjustment for the treatment of COVID\u201019 in the Chinese population.<\/jats:p>","DOI":"10.1111\/cts.70481","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T14:03:51Z","timestamp":1774793031000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open\u2010Label, Fixed Sequence, Phase 1 Study"],"prefix":"10.1111","volume":"19","author":[{"given":"Jixiang","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Drug Clinical Trials Center Peking University Third Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danning","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Drug Clinical Trials Center Peking University Third Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Drug Clinical Trials Center Peking University Third Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei","family":"Yan","sequence":"additional","affiliation":[{"name":"MSD China  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqiao","family":"Zang","sequence":"additional","affiliation":[{"name":"MSD China  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Zhao","sequence":"additional","affiliation":[{"name":"MSD China  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9163-1100","authenticated-orcid":false,"given":"Fang","family":"Sun","sequence":"additional","affiliation":[{"name":"MSD China  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2410-4379","authenticated-orcid":false,"given":"Brian M.","family":"Maas","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5735-1821","authenticated-orcid":false,"given":"Mickie H.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5620-7092","authenticated-orcid":false,"given":"S. Aubrey","family":"Stoch","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8286-2813","authenticated-orcid":false,"given":"Haiyan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Drug Clinical Trials Center Peking University Third Hospital  Beijing China"},{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Cardiology and Institute of Vascular Medicine Peking University Third Hospital  Beijing China"},{"name":"Beijing Key Laboratory of Clinical Evaluation of Cardiovascular\u2010Kidney\u2010Metabolic and Immuno\u2010Inflammatory Innovative Drugs and Medical Devices Peking University Third Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,29]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"World Health Organization WHO COVID\u201019 Dashboard https:\/\/covid19.who.int\/."},{"key":"e_1_2_10_3_1","first-page":"162","article-title":"SARS\u2010CoV\u20102 Variant Biology: Immune Escape, Transmission and Fitness","volume":"21","author":"Carabelli A. M.","year":"2023","journal-title":"Nature Reviews. Microbiology"},{"key":"e_1_2_10_4_1","unstructured":"World Health Organization Disease Outbreak News: Trends of Acute Respiratory Infection Including Human Metapneumovirus in the Northern Hemisphere https:\/\/www.who.int\/emergencies\/disease\u2010outbreak\u2010news\/item\/2025\u2010DON550."},{"key":"e_1_2_10_5_1","unstructured":"Chinese Center for Disease Control and Prevention Novel Coronavirus Infection Situation in China (May 2025) https:\/\/www.chinacdc.cn\/jksj\/xgbdyq\/202506\/t20250605_307356.html."},{"key":"e_1_2_10_6_1","unstructured":"World Health Organization COVID\u201019 Global Situation\u201428 May 2025 https:\/\/www.who.int\/emergencies\/disease\u2010outbreak\u2010news\/item\/2025\u2010DON572."},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid3001.230414"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.46234\/ccdcw2024.092"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/M22-0729"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2281882"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00152-0"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04388-0"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12070781"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02861-3"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.46234\/ccdcw2023.042"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100816"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S456333"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hcs2.36"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb5883"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46490-7"},{"key":"e_1_2_10_21_1","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00953-23","article-title":"Molnupiravir Maintains Antiviral Activity Against SARS\u2010CoV\u20102 Variants and Exhibits a High Barrier to the Development of Resistance","volume":"68","author":"Strizki J. M.","year":"2023","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-022-01170-4"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2214302"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.105970"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax5866"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01348-19"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01965-17"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.122.000918"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104597"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00766-18"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100770"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-021-00651-0"},{"key":"e_1_2_10_33_1","article-title":"Association of Molnupiravir and Nirmatrelvir\u2010Ritonavir With Preventable Mortality, Hospital Admissions and Related Avoidable Healthcare System Cost Among High\u2010Risk Patients With Mild to Moderate COVID\u201019","volume":"30","author":"Wai A. K.","year":"2023","journal-title":"Lancet Regional Health"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116044"},{"key":"e_1_2_10_35_1","article-title":"Molnupiravir and Risk of Hospital Admission or Death in Adults With Covid\u201019: Emulation of a Randomized Target Trial Using Electronic Health Records","volume":"380","author":"Xie Y.","year":"2023","journal-title":"BMJ (Clinical Research ed.)"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01586-0"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.14393"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.06.018"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad409"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00891-1"},{"key":"e_1_2_10_41_1","unstructured":"US Food and Drug Administration Fact Sheet for Healthcare Providers: Emergency Use Authorization for Lagevrio (molnupiravir) Capsules https:\/\/www.fda.gov\/media\/155054\/download."},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02428-20"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13602"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac199"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab318"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13031"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70073"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.61"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13395"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0492-3"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70481","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.70481","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:24:54Z","timestamp":1777955094000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,29]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/cts.70481"],"URL":"https:\/\/doi.org\/10.1111\/cts.70481","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,29]]},"assertion":[{"value":"2025-10-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70481"}}